• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 10-K/A filed by Sharps Technology Inc.

    4/15/25 5:25:35 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care
    Get the next $STSS alert in real time by email
    true FY 0001737995 0001737995 2024-01-01 2024-12-31 0001737995 STSS:CommonStockParValue0.0001Member 2024-01-01 2024-12-31 0001737995 STSS:CommonStockPurchaseWarrantsMember 2024-01-01 2024-12-31 0001737995 2024-06-30 0001737995 2025-03-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 10-K/A

     

    ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the fiscal year ended December 31, 2024

     

    ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Commission file number 001-41355

     

    Sharps Technology, Inc.
    (Exact name of registrant as specified in its charter)

     

    Nevada   82-3751728

    State or other jurisdiction

    of incorporation or organization

     

    (I.R.S. Employer

    Identification No.)

         
    105 Maxess Road, Suite 124, Melville, NY   11747
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s Telephone number, including area code: (631) 574-4436

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol (s)   Name of each exchange on which registered
    Common Stock, Par Value $0.0001   STSS   Nasdaq Capital Market
    Common Stock Purchase Warrants   STSSW   Nasdaq Capital Market

     

    Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registered is a well-known seasonal issuer, as defined in Rule 405 the Securities Act

    Yes ☐ No ☒

     

    Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act Yes ☐ No ☒

     

    Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the last 90 days. Yes ☒ No ☐

     

    Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-K (§229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☒

     

    If an emerging growth company, indicate by a check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

     

    Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

     

    If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

     

    Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

     

    Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

     

    As of June 30, 2024 (the last business day of the registrant’s most recently completed second fiscal quarter), the aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was $6,541,788, based on the closing price on that date as reported on the NASDAQ Capital Market.

     

    As of March 25, 2025, 16,333,897 shares of the registrant’s common stock, par value $.0001 per share, were issued and outstanding.

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    Sharps Technology, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-K/A (the “Amendment”) to its annual report on Form 10-K for the fiscal year ended December 31, 2024, which was originally filed with the Securities and Exchange Commission on March 27, 2024 (the “Original 10-K”).

     

    The purpose of this Amendment No. 1 is to include the Company’s Compensation Recovery Policy annexed as Exhibit 99.1 attached hereto. Except as otherwise expressly noted herein, this Amendment does not amend or otherwise update any other information in our Original 10-K. Accordingly, this Amendment should be read in conjunction with our Original 10-K.

     

    2

     

     

    PART IV

     

    Item 15. Exhibits, Financial Statement Schedules

     

    a) Financial Statements

     

    1) Financial statements for our Company are listed in the index under Item 8 of this document.
       
    2) All financial statement schedules are omitted because they are not applicable, not material or the required information is shown in the financial statements or notes thereto.

     

    3

     

     

    b) Exhibits

     

    Exhibit

    Number

      Description
    1.1   Form of Underwriting Agreement (incorporated by reference to Exhibit 1.1 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    3.1   Articles of Incorporation of Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    3.2   Certificate of Designation of Series A Preferred Stock (incorporated by reference to Exhibit 3.2 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    3.3   Certificate of Amendment to Designation, filed on December 28, 2022 (incorporated by reference to 8-K filed on December 28, 2022)
    3.4   Bylaws of Registrant (incorporated by reference to Exhibit 3.3 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)

    3.5

      Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 of the Registrants Registration Statement on Form S-1; No. 333-284237, originally filed with the Securities and Exchange Commission on January 22, 2025)
    10.1   Asset/Share Purchase Agreement, dated June 10, 2020, among the Company, Safegard Medical (Hungary) Ktf, Numan Holding Ltd, Cortrus Services SA and Latitude Investments Limited (incorporated by reference to Exhibit 10.1 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.2   Amendment No. 1 to Asset/Share Purchase Agreement, dated June 24, 2020 (incorporated by reference to Exhibit 10.2 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.3   Amendment No. 2 to Asset/Share Purchase Agreement, dated August 27, 2020 (incorporated by reference to Exhibit 10.3 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.4   Amendment No. 3 to Asset/Share Purchase Agreement, dated October 28, 2020 (incorporated by reference to Exhibit 10.4 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.5   Amendment No. 4 to Asset/Share Purchase Agreement, dated July 19, 2021 (incorporated by reference to Exhibit 10.5 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.6   Amendment No. 5 to Asset/Share Purchase Agreement, dated February 28, 2022 (incorporated by reference to Exhibit 10.6 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.7   Letter, dated September 23, 2021, from Numan Holding Ltd (incorporated by reference to Exhibit 10.7 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.8   Employment Agreement, dated September 9, 2021, between the Company and Robert Hayes (incorporated by reference to Exhibit 10.8 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.9   Consulting Agreement between the Company and Alan Blackman (incorporated by reference to Exhibit 10.9 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)

     

    4

     

     

    Exhibit

    Number

      Description
    10.10   Amended Consulting Agreement, dated May 28, 2019, between the Company and Barry Berler (incorporated by reference to Exhibit 10.10 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.11   Royalty Agreement, dated July 11, 2017, between Alan Blackman and Barry Berler (incorporated by reference to Exhibit 10.11 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.12   Amendment to Royalty Agreement, dated September 4, 2018 (incorporated by reference to Exhibit 10.12 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.13   Consulting Agreement, dated January 1, 2021, between the Company and Berry Berler (incorporated by reference to Exhibit 10.13 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.14   Note Purchase Agreement, dated December 14, 2021, among the Company and the purchasers named therein (incorporated by reference to Exhibit 10.14 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.15   Form of Note (incorporated by reference to Exhibit 10.15 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.16   Security Agreement among the Company and the secured parties named therein (incorporated by reference to Exhibit 10.16 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.17   Consent to be named as a director nominee of Jason Monroe (incorporated by reference to Exhibit 10.17 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.18   Consent to be named as a director nominee of Brenda Baird Simpson (incorporated by reference to Exhibit 10.18 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.19   Form of Warrant for this offering (incorporated by reference to Exhibit 10.19 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.20   Form of Pre-Funded Warrant for this offering (incorporated by reference to Exhibit 10.20 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.21   Form of Warrant Agent Agreement (Pre-Funded Warrants) (incorporated by reference to Exhibit 10.21 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.22   2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.22 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.23   Plan and Agreement of Merger, dated March 22, 2022, between Sharps Technology, Inc., a Wyoming corporation, and Sharps Technology, Inc., a Nevada corporation (incorporated by reference to Exhibit 10.23 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.24   Form of Warrant Agent Agreement (Warrants) (incorporated by reference to Exhibit 10.24 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.25   Form of Representative’s Warrant (incorporated by reference to Exhibit 10.25 of the Registrant’s Registration Statement on Form S-1; No. 333-263715, as amended, originally filed with the Securities and Exchange Commission on March 18, 2022)
    10.26   2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.36 of the Registrant’s Registration Statement on Form S-1; 333-284237, originally filed on January 22, 2025)
    23.1*   Consent of PKF O’Connor Davies LLP

     

    5

     

     

    Exhibit

    Number

      Description
    31.1*   Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act, as amended.
    31.2*   Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act, as amended.
    32.1**   Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rules 13a-14(b) or 15d-14(b) of the Securities Exchange Act, as amended, and 18 U.S.C. Section 1350.
    99.1*   Compensation Recovery Policy
         
    101.INS   Inline XBRL Instance Document
         
    101.SCH   Inline XBRL Taxonomy Extension Schema Document
         
    101.CAL   Inline XBRL Taxonomy Extension Definition Link
         
    101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
         
    101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
         
    101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
         
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    * Filed herewith.
    ** Furnished herewith.
    + Indicates management contract or compensatory plan.

     

    6

     

     

    SIGNATURES

     

    In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 15th day of April 2025.

     

    SHARPS TECHNOLOGY, INC.  
       
    By: /s/ Robert M. Hayes  
      Robert M. Hayes  
      Chief Executive Officer and Director  

     

    Signature   Title   Date
             
    /s/ Robert M. Hayes   Chief Executive Officer and Director   April 15, 2025
    Robert M. Hayes   (Principal Executive Officer)    
             
    /s/ Andrew R. Crescenzo   Chief Financial Officer   April 15, 2025
    Andrew R. Crescenzo   (Principal Financial and Accounting Officer)    
             
    /s/ Dr. Soren Bo Christiansen*   Chairman   April 15, 2025
    Dr Soren Bo Christiansen        
             
    /s/ Paul K. Danner*   Director   April 15, 2025
    Paul K. Danner        
             
    /s/ Timothy J. Ruemler*   Director   April 15, 2025
    Timothy J. Ruemler        
             
    /s/ Brenda Baird Simpson*   Director   April 15, 2025
    Brenda Baird Simpson        
             
    /s/ Jason L. Monroe*   Director   April 15, 2025
    Jason L. Monroe        

     

    * By: /s/ Robert M. Hayes  
      Attorney-in-fact  

     

    7

     

     

    Get the next $STSS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STSS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $STSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Bank Of America Corp /De/

      4 - Sharps Technology Inc. (0001737995) (Issuer)

      5/6/25 4:27:50 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Hayes Robert Michael bought $10,750 worth of shares (300,000 units at $0.04), increasing direct ownership by 297% to 400,882 units (SEC Form 4)

      4 - Sharps Technology Inc. (0001737995) (Issuer)

      4/1/25 5:24:02 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Amendment: Chief Executive Officer Hayes Robert Michael bought $10,072 worth of shares (5,000 units at $2.01), increasing direct ownership by 115% to 9,358 units (SEC Form 4)

      4/A - Sharps Technology Inc. (0001737995) (Issuer)

      12/6/24 5:15:10 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care

    $STSS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sharps Technology Receives ~$100K Initial Purchase Order from Hungarian Vaccine Provider for SecureGard™ Syringes

      Sharps also received an initial qualification purchase order for DisGard™ single-use Sharps Recovery System Company transitions to revenue producing with second purchase order, bringing total recent orders to approximately $500,000 for the quarter NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: "STSS" and "STSSW") ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, announces the receipt of a $100,000 purchase order from a Hungarian vaccine provider. This order supports the recently announced $400,000 SoloGard™ order, which is part o

      5/6/25 7:00:00 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Sharps Technology Secures $400K Initial Purchase Order from U.S. Leader in IV Flushing Solutions as Part of $50 Million SoloGard Supply Agreement

      Milestone order marks first commercial revenue for Sharps Technology under multi-year, 500-million syringe agreementInvestments in best-in-class manufacturing equipment position Sharps to offer differentiated high-volume syringe production to meet long-term contract demand NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: "STSS" and "STSSW") ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, today announced the receipt of a $400,000 purchase order from a U.S. leader in IV flushing solutions. This marks the first order under the previously announ

      4/30/25 7:00:00 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Sharps Technology Announces Reverse Stock Split

      NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: "STSS" and "STSSW") ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, today announced that it will effect a 1-for-300 reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on April 27, 2025 at 11:59 PM Eastern Time, before the opening of trading on The Nasdaq Capital Market ("Nasdaq"). Sharps has requested that its Common Stock begin trading on April 28, 2025, on a post-reverse split basis on the Nasdaq under th

      4/24/25 11:00:00 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care

    $STSS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Hayes Robert Michael bought $10,750 worth of shares (300,000 units at $0.04), increasing direct ownership by 297% to 400,882 units (SEC Form 4)

      4 - Sharps Technology Inc. (0001737995) (Issuer)

      4/1/25 5:24:02 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Amendment: Chief Executive Officer Hayes Robert Michael bought $10,072 worth of shares (5,000 units at $2.01), increasing direct ownership by 115% to 9,358 units (SEC Form 4)

      4/A - Sharps Technology Inc. (0001737995) (Issuer)

      12/6/24 5:15:10 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Hayes Robert Michael bought $10,072 worth of shares (5,000 units at $2.01), increasing direct ownership by 5% to 100,882 units (SEC Form 4)

      4 - Sharps Technology Inc. (0001737995) (Issuer)

      12/5/24 6:12:59 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care

    $STSS
    Leadership Updates

    Live Leadership Updates

    See more

    $STSS
    SEC Filings

    See more
    • Sharps Technology Planning To Collaborate With Roncadelle To Support Global Distribution And Sales Of High Quality, Innovative, Safer Drug Delivery Systems

      NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ:STSS) (NASDAQ:STSSW), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is working to create new sales and distribution opportunities through the addition of new North American 3PL partnerships to expand its reach into the global healthcare market. These additional third-party logistics partnerships, along with a developing alliance with Roncadelle Operations, a driving force in the development of safe, novel medical drug delivery devices, would combine the strengths and capabilities of the two companies to develop, market and distribute unique dru

      2/16/24 2:42:54 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Sharps Technology Appoints Industry Sales and Manufacturing Leader Ben Scheu as Senior Director of Sales

      Key appointment with demonstrated experience in leading sales and marketing operations to oversee commercial initiatives as the Company launches its specialty smart safety syringe products to the market Product qualification and sales initiatives underway as company prepares for U.S. commercial operations NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the "Company") (NASDAQ: "STSS" and "STSSW"), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, is pleased to announce the appointment of Ben Scheu as Senior Director of Sales to lead commercial operations as the Company prepares to launch products to the market.

      7/12/23 8:33:00 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Sharps Technology Appoints Justin Page as Vice President of Technical Operations

      NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the "Company", "Sharps") (NASDAQ: "STSS" and "STSSW"), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, appoints Justin Page as Vice President of Technical Operations. In his role, Mr. Page will be responsible for managing all aspects of Sharps' engineering operations. His primary focus will be to provide the leadership and technical expertise to support the prefillable syringe collaboration with Nephron Pharmaceuticals at the InjectEZ facility. These efforts will include the support for the injection molding of the specialty components and the high speed assembl

      2/9/23 9:21:23 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • SEC Form SCHEDULE 13G filed by Sharps Technology Inc.

      SCHEDULE 13G - Sharps Technology Inc. (0001737995) (Subject)

      5/7/25 3:55:46 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Sharps Technology Inc. filed SEC Form 8-K: Other Events

      8-K - Sharps Technology Inc. (0001737995) (Filer)

      5/7/25 9:00:22 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Sharps Technology Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Sharps Technology Inc. (0001737995) (Filer)

      5/6/25 8:00:37 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care

    $STSS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sharps Technology Inc.

      SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)

      11/13/24 4:50:17 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sharps Technology Inc.

      SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)

      10/9/24 9:01:14 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Sharps Technology Inc.

      SC 13G - Sharps Technology Inc. (0001737995) (Subject)

      2/14/24 11:14:11 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care

    $STSS
    Financials

    Live finance-specific insights

    See more
    • Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (NASDAQ:SNGX) and Sharps Technology Inc. (NASDAQ:STSS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 8, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Soligenix: https://www.redchip.com/assets/access/sngx_accessSharps Technology: https://www.redchip.com/assets/access/stss_accessIn an exclusive interview, Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix, appears on the RedChip Small Stocks Big Money™ show on B

      6/7/24 9:00:00 AM ET
      $SNGX
      $STSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / September 29, 2023 / RedChip Companies will air interviews with Sharps Technology, Inc. (NASDAQ:STSS), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and American Resources Corp. (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Sharps Technology: https://www.redchip.com/assets/access/stss_accessReviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAmerican Resources Corp: https://www.redchip.com/assets/access/arec_accessAbout The RedChip

      9/29/23 9:00:00 AM ET
      $AREC
      $RVPH
      $STSS
      Coal Mining
      Energy
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RedChip Launches 'Small Stocks, Big Money' Podcast

      New podcast series shines a spotlight on undervalued small-cap and microcap stocksORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap companies,announce the launch of its much-anticipated podcast series, "Small Stocks, Big Money."Hosted by RedChip CEO Dave Gentry and Associate Director Barrett Boone, the "Small Stocks, Big Money" podcast aims to offer a first-hand look at undiscovered small-cap and microcap stocks before they catch the attention of bigger Wall Street players. The series features in-depth interviews with executives from some of the top names in smaller cap stocks, providing list

      8/2/23 12:45:00 PM ET
      $BFRG
      $LTRN
      $RVPH
      $STSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Pharmaceuticals and Biotechnology